Calmark’s Italian distributor places order for COVID19-LDH demo units

Report this content

Calmark Sweden AB (publ) announces today that an order has been received from the Company’s Italian distributor P.R.I.S.M.A. Srl (Prisma).

As previously disclosed on November 26, 2020, an exclusive distributor agreement covering Calmark’s test for assessment of COVID-19 disease severity has been signed with Prisma. The agreement contains a minimum contract volume of MSEK 4.6.

“We are happy that Prisma now is eager to get started with demonstrating and getting to know the product,” says Magdalena Tharaldsen, Director International Business Development at Calmark. “It feels good to be able to supply such a vital product to Italy, where the situation has been dire for a long time. There is a need there for a reliable measuring instrument with analysis results that can provide critical decision support in the assessment of which patients are in genuine need of intensive care.”

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.


For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at  


Documents & Links